EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation

Ehab M. Elzayat, Sultan Almutairy, Abdelrahman Y. Sherif, Mohamed M. Badran, Mohammad A. Altamimi

Pharmaceutics · 18.11.2026 · 18 (11) · 1487

DOI: 10.3390/pharmaceutics18111487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.11.2026. Verfasst von Ehab M. Elzayat und 4 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Ischemic brain injury involves parallel oxidative, inflammatory, and vascular cascades. Olmesartan medoxomil and apigenin act on complementary arms and can serve this purpose. This study developed a self-nanoemulsifying drug delivery system (SNEDDS) co-loaded with both agents for intranasal use. Constrained mixture design was used to determine its actual composition.

Methods

Oil and cosolvent were selected by saturation solubility and surfactant by emulsification transmittance. The proportions of Kolliphor EL (40–70% w/w), poly(ethylene glycol) 400 (5–30% w/w), and Imwitor 308 (20–40% w/w) were treated as mixture variables and each drug’s solubility as the response. Desirability analysis identified the optimum composition, which was experimentally verified. After that, it was compared with a drug suspension for permeation across excised goat nasal mucosa in Franz diffusion cells.

Results

Apigenin solubility followed a linear mixture model and olmesartan medoxomil a quadratic model. The optimum composition (52.33% Kolliphor EL, 27.67% poly(ethylene glycol) 400, 20.00% Imwitor 308) gave observed solubilities of 11.82 and 6.91 mg/g, within the 95% prediction intervals. Steady-state flux rose from 0.85 ± 0.68 to 8.46 ± 2.51 µg/cm2/h for olmesartan medoxomil and from 0.18 ± 0.17 to 10.06 ± 3.63 µg/cm2/h for apigenin.

Conclusions

A constrained mixture design identified a SNEDDS composition that accommodated both drugs and markedly increased their transport across excised nasal mucosa relative to a suspension. These findings establish a formulation basis for the intranasal administration of this drug combination.

Förderung

  • King Saud University

Zitieren

APA

Elzayat, E. M., Almutairy, S., Sherif, A. Y., Badran, M. M., & Altamimi, M. A. (2026). Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation. Pharmaceutics, 18(11), 1487. https://doi.org/10.3390/pharmaceutics18111487

Vancouver

Elzayat EM, Almutairy S, Sherif AY, Badran MM, Altamimi MA. Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation. Pharmaceutics. 2026;18(11):1487. doi:10.3390/pharmaceutics18111487

BibTeX
@article{Elzayat2026,
  author = {Elzayat, Ehab M. and Almutairy, Sultan and Sherif, Abdelrahman Y. and Badran, Mohamed M. and Altamimi, Mohammad A.},
  title = {Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1487},
  doi = {10.3390/pharmaceutics18111487}
}
Kostenlos starten →